Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 32904468.
- Also identified by DOI 10.1016/j.xcrm.2020.100092 and PMC identifier 7456276.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T cell immunity toward SARS-CoV-2 spike (S-), membrane (M-), and nucleocapsid (N-) proteins may define COVID-19 severity. Therefore, we compare the SARS-CoV-2-reactive T cell responses in moderate, severe, and critical COVID-19 patients and unexposed donors. Overlapping peptide pools of all three proteins induce SARS-CoV-2-reactive T cell response with dominance of CD4<sup>+</sup> over CD8<sup>+</sup> T cells and demonstrate interindividual immunity against the three proteins. M-protein induces the highest frequencies of CD4<sup>+</sup> T cells, suggesting its relevance for diagnosis and vaccination. The T cell response of critical COVID-19 patients is robust and comparable or even superior to non-critical patients. Virus clearance and COVID-19 survival are not associated with either SARS-CoV-2 T cell kinetics or magnitude of T cell responses, respectively. Thus, our data do not support the hypothesis of insufficient SARS-CoV-2-reactive immunity in critical COVID-19. Conversely, it indicates that activation of differentiated memory effector T cells could cause hyperreactivity and immunopathogenesis in critical patients.
Medical subject headings
- COVID-19
- Coronavirus M Proteins
- Coronavirus Nucleocapsid Proteins
- Spike Glycoprotein, Coronavirus
- T-Lymphocytes